Thyroid status and nitric oxide in rat arterial vessels

R M McAllister, I Albarracin, E M Price1, T K Smith, J R Turk1 and K D Wyatt

Departments of Anatomy and Physiology and Kinesiology, Kansas State University, Manhattan, Kansas 66506, USA
1Department of Veterinary Biomedical Sciences, University of Missouri, Columbia, Missouri 65211, USA

(Requests for offprints should be addressed to R M McAllister, Department of Anatomy and Physiology, Kansas State University, 228 Coles Hall, Manhattan, Kansas 66506, USA; Email: mcallist@vet.ksu.edu)

Abstract

Thyroid disease has profound effects on cardiovascular function. Hypo- and hyperthyroidism, for example, are associated with reduced and increased maximal endothelium-dependent vasodilation respectively. We therefore hypothesized that the capacity for vascular nitric oxide (NO) formation is decreased in hypothyroidism and increased in hyperthyroidism. To test this hypothesis, rats were made hypothyroid (HYPO) with propylthiouracil or hyperthyroid (HYPER) with triiodothyronine over 3–4 months. Compared with euthyroid control rats (EUT), HYPO exhibited blunted growth and lower citrate synthase activity in the soleus muscle; HYPER exhibited left ventricular hypertrophy and higher citrate synthase activity in the soleus muscle (P<0·05 for all effects). The capacity for NO formation was determined in aortic extracts by formation of [3H]l-citrulline from [3H]l-arginine, i.e. NO synthase (NOS) activity. Thyroid status modulated NOS activity (EUT, 36·8 ± 5·5 fmol/h per mg protein; HYPO, 26·0 ± 7·9; HYPER, 64·6 ± 12·7; P<0·05, HYPER vs HYPO). Expression of endothelial and neural isoforms of NOS was modulated by thyroid status in a parallel fashion. Capacity for responding to NO was also determined via measuring cGMP concentration in aortae incubated with sodium nitroprusside. Stimulated cGMP formation was also modulated by thyroid status (EUT, 73·0 ± 20·2 pmol/mg protein; HYPO, 152·4 ± 48·7; HYPER, 10·4 ± 2·6; P<0·05, HYPER vs HYPO). These data indicate that thyroid status alters capacities for both formation of and responding to NO. The former finding may contribute to previous findings concerning vascular function in thyroid disease states.

Journal of Endocrinology (2005) 185, 111–119

Introduction

Thyroid disease is estimated to affect 10% of the population (Tunbridge & Caldwell 1991, Canaris et al. 2000). A hallmark of two common forms of thyroid disease, hypo- and hyperthyroidism, is exercise intolerance. Several studies have examined various mechanisms potentially responsible for exercise intolerance in these disease states. In hypothyroidism, it appears that cardiovascular dysfunction is largely responsible for poor exercise tolerance; in hyperthyroidism, other factors such as hyperthermia and altered patterns of substrate utilization are implicated (cf. McAllister et al. 1995a).

Cardiovascular dysfunction during exercise in hypothyroidism is profound. We have previously reported that skeletal muscle blood flow during treadmill running is reduced ~50% in hypothyroid rats compared with their euthyroid counterparts (McAllister et al. 1995b). Lower blood flow would impair delivery of O2 and substrates to exercising muscle. When vasomotor responses were determined for euthyroid and hypothyroid rats, endothelium-dependent dilation was also found to be blunted in isolated aortae (Delp et al. 1995, McAllister et al. 2000) and isolated perfused kidneys (Vargas et al. 1995) in the hypothyroid state. Paradoxically, given that exercise tolerance is reduced, hyperthyroidism is associated with enhanced muscle blood flow during exercise (Frey 1967, McAllister et al. 1995a) and augmented endothelium-dependent vasodilation (Scivoletto et al. 1986, Vargas et al. 1995, McAllister et al. 1998, 2000, Honda et al. 2000). Thus, in both thyroid disease states, alterations in endothelium-dependent vasodilation are consistent with patterns of blood flow to exercising skeletal muscle.

Endothelium-independent vasodilation has generally been reported to be normal in both the hypothyroid (Delp et al. 1995, McAllister et al. 2000) and hyperthyroid states (McAllister et al. 1998, 2000), although exceptions have been reported (Vargas et al. 1995, Honda et al. 2000). Collectively, these findings suggest that thyroid status primarily affects the vascular endothelium. Endothelium-dependent dilation of the rat aorta is primarily mediated by nitric oxide (NO) (Delp et al. 1993). We therefore hypothesized that altered endothelium-dependent vasodilation with changes in thyroid status is due to changes
in the capacity for NO formation, as reflected by NO synthase (NOS) activity. We also hypothesized that the
response to NO, as reflected by the capacity of vascular smooth muscle to generate cGMP, is not altered by
thyroid status.

**Materials and Methods**

*Animal treatments*

Two series of male Sprague–Dawley rats (Charles River,
Wilmington, MA, USA), initially weighing 150–175 g,
were housed three per cage in a room with controlled
temperature (20–21 °C) and light (12 h light:12 h dark-
ness). In each series, rats were randomly assigned to one
of three groups: euthyroid control (EUT), hypothyroid
(HYPO) and hyperthyroid (HYPER). HYPO rats were
made hypothyroid over a 3–4 month period with propyl-
thiouracil in their drinking water (0·04 g/100 ml), as done
previously (Delp *et al.* 1995, McAllister *et al.* 1995b,c, 1998, 2000). HYPER rats were made hyperthyroid over 3–4
months with i.p. injections of triiodothyronine (300 µg/kg in
0·50 mM NaOH) on alternate days, as done previously
(McAllister *et al.* 1995,c, 1998, 2000) All rats were allowed
free access to food and water except for EUT, which were
slightly food-restricted (∼90% of normal food intake) over
the final month of the treatment period to match body
weights with those of HYPO and HYPER. This mild
degree of food restriction would not affect thyroid status in
EUT, since only either starvation or severe food restriction
has been reported to reduce thyroid hormone levels (cf.
Danforth & Burger 1989). All treatments were approved
by the Institutional Animal Care and Use Committee of
Kansas State University, and were in accordance with the
NIH Guide for the Care and Use of Laboratory Animals.

*Treatment efficacy*

Efficacy of propylthiouracil and triiodothyronine treat-
ments was assessed by determination of citrate synthase
activity in the soleus muscle, gain in body weight during
the treatment period and left ventricular weight/body
weight ratio. Activity of citrate synthase, a marker enzyme
for oxidative capacity, was determined spectrophotometri-
cally (Shimadzu UV-1201, Shimadzu, Kyota, Japan) ac-
cording to the method of Srere (1969), as done previously
to document hypo- and hyperthyroidism (Delp *et al.* 1995,

*NOS activity*

With the first series of rats (NOS Series), capacity for
vascular NO formation was assessed by determining NOS
activity in aortic extracts of EUT, HYPO and HYPER.
Extracts of aortae were prepared in the following manner:

the entire aorta was excised, quickly cleaned of fat and
connective tissue under a dissecting microscope (Nikon,
Melville, NY, USA), and cut into rings ∼1 mm in axial
length. Vascular rings were transferred to microcentrifuge
tubes containing 250 µl of a buffer solution containing (in
mM unless otherwise indicated): 50 Tris–HCl, 0·10
EDTA, 0·10 EGTA, 0·10 ml/100 ml β-mercaptoethanol,
20 CHAPS, 1·0 phenylmethylsulfonyl fluoride, 0·002
leupeptin and 0·001 pepstatin A, pH 7·8. Vascular rings
were sonicated (Fisher Sonic Dismembrator 60, Fisher,
Pittsburgh, PA, USA) in this buffer solution (5 s, three
times), and then centrifuged at 250 000 g (Beckman
TL-100 ultracentrifuge, Beckman, Palo Alto, CA, USA)
for 30 min at 4 °C. Aliquots of the resultant supernatant
were assayed for NOS activity.

NOS activity was determined according to the method
of Pollock *et al.* (1991), in which the conversion of
[1H]−arginine to [1H]−citrulline is measured. Aortic
extracts were incubated for 1 h at 27 °C in a buffer
solution with (final concentration, in mM unless otherwise
indicated): 50 Tris–HCl, 54 t-valine, 1·2 MgCl2, 1·0
NADPH, 0·01 tetrahydrobiopterin, 0·005 t-arginine, 50
U/ml calmodulin and 0·002 FAD, pH 7·8. [1H]−arginine
(0·010 mCi; New England Nuclear, Boston, MA, USA)
was also included. Aliquots of extracts were incubated in
this buffer solution that contained CaCl2 (1·78 mM) and
in buffer solution that did not contain CaCl2 to determine
Ca2+-dependent NOS activity. Appropriate backgrounds
(i.e. aliquots of buffer solution rather than aortic extract)
were incubated in parallel. At the end of the incubation
period, the NOS reaction was arrested with addition of a
buffer solution containing 20 mM HEPES and 8·0 mM
EDTA, pH 5·5. Reaction mixtures were loaded onto
cation exchange columns (Dowex AG 50WX-8, Na+
form; Bio-Rad), and [3H]−arginine (CI nium 1 mm in axial
length. Vascular rings were transferred to microcentrifuge
tubes containing 250 µl of a buffer solution containing (in
mM unless otherwise indicated): 50 Tris–HCl, 0·10
EDTA, 0·10 EGTA, 0·10 ml/100 ml β-mercaptoethanol,
20 CHAPS, 1·0 phenylmethylsulfonyl fluoride, 0·002
leupeptin and 0·001 pepstatin A, pH 7·8. Vascular rings
were sonicated (Fisher Sonic Dismembrator 60, Fisher,
Pittsburgh, PA, USA) in this buffer solution (5 s, three
times), and then centrifuged at 250 000 g (Beckman
TL-100 ultracentrifuge, Beckman, Palo Alto, CA, USA)
for 30 min at 4 °C. Aliquots of the resultant supernatant
were assayed for NOS activity.

NOS activity was determined according to the method
of Pollock *et al.* (1991), in which the conversion of
[1H]−arginine to [1H]−citrulline is measured. Aortic
extracts were incubated for 1 h at 27 °C in a buffer
solution with (final concentration, in mM unless otherwise
indicated): 50 Tris–HCl, 54 t-valine, 1·2 MgCl2, 1·0
NADPH, 0·01 tetrahydrobiopterin, 0·005 t-arginine, 50
U/ml calmodulin and 0·002 FAD, pH 7·8. [1H]−arginine
(0·010 mCi; New England Nuclear, Boston, MA, USA)
was also included. Aliquots of extracts were incubated in
this buffer solution that contained CaCl2 (1·78 mM) and
in buffer solution that did not contain CaCl2 to determine
Ca2+-dependent NOS activity. Appropriate backgrounds
(i.e. aliquots of buffer solution rather than aortic extract)
were incubated in parallel. At the end of the incubation
period, the NOS reaction was arrested with addition of a
buffer solution containing 20 mM HEPES and 8·0 mM
EDTA, pH 5·5. Reaction mixtures were loaded onto
cation exchange columns (Dowex AG 50WX-8, Na+
form; Bio-Rad), and [1H]−arginine (CI nium 1 mm in axial
length. Vascular rings were transferred to microcentrifuge
tubes containing 250 µl of a buffer solution containing (in
mM unless otherwise indicated): 50 Tris–HCl, 0·10
EDTA, 0·10 EGTA, 0·10 ml/100 ml β-mercaptoethanol,
20 CHAPS, 1·0 phenylmethylsulfonyl fluoride, 0·002
leupeptin and 0·001 pepstatin A, pH 7·8. Vascular rings
were sonicated (Fisher Sonic Dismembrator 60, Fisher,
Pittsburgh, PA, USA) in this buffer solution (5 s, three
times), and then centrifuged at 250 000 g (Beckman
TL-100 ultracentrifuge, Beckman, Palo Alto, CA, USA)
for 30 min at 4 °C. Aliquots of the resultant supernatant
were assayed for NOS activity.

NOS activity was determined according to the method
of Pollock *et al.* (1991), in which the conversion of
[1H]−arginine to [1H]−citrulline is measured. Aortic
extracts were incubated for 1 h at 27 °C in a buffer
solution with (final concentration, in mM unless otherwise
indicated): 50 Tris–HCl, 54 t-valine, 1·2 MgCl2, 1·0
NADPH, 0·01 tetrahydrobiopterin, 0·005 t-arginine, 50
U/ml calmodulin and 0·002 FAD, pH 7·8. [1H]−arginine
(0·010 mCi; New England Nuclear, Boston, MA, USA)
was also included. Aliquots of extracts were incubated in
this buffer solution that contained CaCl2 (1·78 mM) and
in buffer solution that did not contain CaCl2 to determine
Ca2+-dependent NOS activity. Appropriate backgrounds
(i.e. aliquots of buffer solution rather than aortic extract)
were incubated in parallel. At the end of the incubation
period, the NOS reaction was arrested with addition of a
buffer solution containing 20 mM HEPES and 8·0 mM
EDTA, pH 5·5. Reaction mixtures were loaded onto
cation exchange columns (Dowex AG 50WX-8, Na+
form; Bio-Rad), and [1H]−arginine (CI nium 1 mm in axial
length. Vascular rings were transferred to microcentrifuge
tubes containing 250 µl of a buffer solution containing (in
mM unless otherwise indicated): 50 Tris–HCl, 0·10
EDTA, 0·10 EGTA, 0·10 ml/100 ml β-mercaptoethanol,
20 CHAPS, 1·0 phenylmethylsulfonyl fluoride, 0·002
leupeptin and 0·001 pepstatin A, pH 7·8. Vascular rings
(in TBST–milk) against eNOS (1:1250; BD Transduction Laboratories), nNOS (1:1000; BD Transduction Laboratories), GC (1:5000; Cayman Chemical, Ann Arbor, MI, USA), or glyceraldehyde–3-phosphate dehydrogenase (GAPDH) (1:2000; Chemicon, Temecula, CA, USA) was done. Separate membranes were generated and probed for eNOS, nNOS and GC; all membranes were subsequently re-probed for GAPDH. After washing, blots were incubated for 60 min with a secondary antibody (horseradish peroxidase-conjugated anti-mouse; 1:2500, in TBST–milk; Sigma–Aldrich), washed, and then visualized on film using enhanced chemiluminescence (Amersham Pharmacia Biotech). Densitometry software (NIH) was used to quantify protein expression, with eNOS, nNOS and GC expression being normalized to GAPDH expression.

Immunohistochemistry
As described in detail previously (Henderson et al. 2004), 5 μm sections of fixed (10 ml/100 ml formalin), paraffin-embedded aortic rings were cut with an automated microtome (Microm, Walldorf, Germany), floated onto positively-charged slides, and de-paraffinized. Sections were incubated with avidin–biotin two-step blocking solution (Vector SP–2001, Vector, Burlingame, CA, USA) to inhibit background staining and with hydrogen peroxide (3 ml/100 ml) to inhibit endogenous peroxidase. Non-serum protein block (Dako X909, Dako, Carpinteria, CA, USA) was used to inhibit non-specific binding. Tissue sections were incubated overnight with primary antibodies against eNOS (mouse monoclonal, 1:800; BD Transduction Laboratories, San Diego, CA, USA) and nNOS (rabbit polyclonal, 1:100; Zymed, San Francisco, CA, USA) at 4 °C. After washing, sections were incubated with biotinylated anti-mouse or rabbit secondary antibodies in PBS containing 15 mM sodium azide and peroxidase-labeled streptavidin (Dako LSAB+ kit, peroxidase; K0690). For negative controls, histological sections were prepared as described above, but incubation with primary antibody was excluded from the protocol. Sections were examined and photographed using an Olympus BX40 photomicroscope (Olympus, St. Louis, MO, USA).

cGMP formation
With the second series of rats (cGMP Series), the concentration of cGMP under basal conditions and upon stimulation with an NO donor was determined in aortae from EUT, HYPO and HYPER. To prepare aortae for cGMP determination, vessels previously excised, cleaned and frozen at −80 °C (entire aorta for basal levels, abdominal aorta for stimulated levels) were opened longitudinally, pinned to the bottom of a dissecting dish filled with ice-cold DMEM–HEPES modification buffer solution, pH 7-4, and gently demuded of their endothelium with a cotton-tipped applicator. Vessels were then placed in DMEM–HEPES modification buffer solution with 1·0 mM isobutylmethylxanthine, pH 7·4 (basal) or the same buffer solution with 10−4 M sodium nitroprusside, an NO donor, also included (stimulated). After a 30 min incubation period, the GC reaction was arrested with 70% trichloroacetic acid and then neutralized with 10·0 M KOH. Vessels were homogenized (IKA Labortechnik T25 homogenizer, Labortechnik, Staufen, Germany) using 10 s bursts until complete homogenization was achieved. Homogenates were centrifuged (Damon PR–J centrifuge) at 1500 g for 10 min. The resultant supernatant was assayed for cGMP concentration; the pellet was used for determination of protein concentration (see below). Concentrations of cGMP in supernatants was determined using an RIA kit (Amersham Pharmacia Biotech).

In addition to determining aortic cGMP concentration, experiments were conducted to determine release of cGMP from aortae. Stimulation of cGMP formation in whole aortae (sectioned into 1 mm axial length rings) using an NO donor was done as described above. After centrifugation (1500 g for 10 min) to pellet aortic rings, cGMP concentration in supernatants was determined with an enzyme immunoassay kit (Assay Designs, Ann Arbor, MI, USA).

Protein concentration
Protein concentration was determined on aortic extracts to normalize NOS activities, and on pellets of homogenized vessels to normalize cGMP concentrations. Protein concentration was determined with a kit utilizing the Bradford procedure (Bio–Rad).

Statistical analysis
All data are presented as means ± S.E. Data for EUT, HYPO and HYPER were analyzed using one-way ANOVA (Steel & Torrie 1980). When ANOVA indicated a difference among groups, the Tukey test was used as a post-hoc test to discern differences between pairs of groups (Steel & Torrie 1980). P<0·05 was considered significant for all analyses.

Results
Treatment efficacy
Treatment of rats with propylthiouracil successfully induced the hypothyroid state. Citrate synthase activity was lower in HYPO than EUT in the soleus muscle for both series of rats (Fig. 1). In addition, HYPO failed to increase body weight at a normal rate, reflected by lower final body weights than those of EUT and HYPER, in both series (Table 1). Similarly, two lines of evidence indicated that treatment of rats with triiodothyronine induced the
hyperthyroid state. First, citrate synthase activity was increased in HYPER (vs EUT) soleus muscles in both series of rats (Fig. 1). Secondly, left ventricular weight/body weight ratio was increased in HYPER compared with EUT (Table 1), reflecting left ventricular hypertrophy.

NOS activity and expression

Figure 2 illustrates \( \text{Ca}^{2+} \)-dependent NOS activity for EUT, HYPO and HYPER aortic extracts. Thyroid status significantly modulated NOS activity, with values for HYPER being more than twice those for HYPO \((P<0.05)\) for EUT, HYPO and Hyperthyroid respectively in the NOS Series. \( * \) Different from Euthyroid, \( P<0.05; † \) different from Hypothyroid, \( P<0.05. \)

<table>
<thead>
<tr>
<th></th>
<th>NOS Series</th>
<th>cGMP Series</th>
</tr>
</thead>
<tbody>
<tr>
<td>LV weight/body weight ratio (mg/g)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euthyroid</td>
<td>2.03 ± 0.08</td>
<td>1.93 ± 0.03</td>
</tr>
<tr>
<td>Hypothyroid</td>
<td>1.86 ± 0.05</td>
<td>2.10 ± 0.06</td>
</tr>
<tr>
<td>Hyperthyroid</td>
<td>2.50 ± 0.10†</td>
<td>2.45 ± 0.07†</td>
</tr>
<tr>
<td>Final body weight (g)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Euthyroid</td>
<td>497 ± 15</td>
<td>516 ± 15</td>
</tr>
<tr>
<td>Hypothyroid</td>
<td>284 ± 6*</td>
<td>253 ± 6*</td>
</tr>
<tr>
<td>Hyperthyroid</td>
<td>478 ± 15†</td>
<td>493 ± 15†</td>
</tr>
</tbody>
</table>

LV, left ventricle. \( * \) Different from Euthyroid in same series, \( P<0.05; † \) different from Hypothyroid in same series, \( P<0.05. \)

Figure 1 Citrate synthase activity in soleus muscles of rats of the NOS Series and cGMP Series. Values are means ± s.e.; \( n=7,7 \) and \( 8 \) for Euthyroid (open bars), Hypothyroid (hatched bars) and Hyperthyroid (stippled bars) respectively in the NOS Series; \( n=12,11 \) and \( 10 \) for Euthyroid, Hypothyroid and Hyperthyroid respectively in the cGMP Series. \( * \) Different from Euthyroid, \( P<0.05; † \) different from Hypothyroid, \( P<0.05. \)

Table 1 Indicators of treatment efficacy. Values are means ± s.e. For NOS Series \( n=7,7 \) and \( 8 \) for Euthyroid, Hypothyroid and Hyperthyroid respectively; for cGMP Series \( n=12,10 \) and \( 10 \) for Euthyroid, Hypothyroid and Hyperthyroid respectively.

Table 1 Indicators of treatment efficacy. Values are means ± s.e. For NOS Series \( n=7,7 \) and \( 8 \) for Euthyroid, Hypothyroid and Hyperthyroid respectively; for cGMP Series \( n=12,10 \) and \( 10 \) for Euthyroid, Hypothyroid and Hyperthyroid respectively.

Basal levels of cGMP were not different among groups, being \( 0.214 \pm 0.055, \ 0.181 \pm 0.051 \) and \( 0.101 \pm 0.027 \) pmol/mg protein for EUT \((n=4)\), HYPO \((n=3)\) and HYPER \((n=4)\) respectively. Figure 6A illustrates data for stimulated levels of cGMP. Stimulation of GC with sodium nitroprusside increased cGMP concentration substantially over basal levels for EUT, HYPO and HYPER. Stimulated cGMP concentration attained was, similar to NOS activity, significantly modulated by thyroid status. Values for HYPO were significantly greater than those for HYPER \((P<0.05)\); however, neither HYPO nor HYPER were significantly different from EUT. GC protein expression did not differ significantly among groups (Fig. 6B).

cGMP concentration

Thyroid status can affect tissue protein concentration; thus, data for cGMP levels were also expressed and analyzed on a per tissue weight basis. Thyroid status did not affect basal cGMP concentration \((EUT, 7.2 \pm 1.0 \) pmol/g; HYPO, \( 12.7 \pm 3.2 \); HYPER, \( 6.2 \pm 1.5; \) ns). Stimulated cGMP concentration was, however, modulated by thyroid state \((EUT, 46.3 \pm 11.0 \) pmol/g; HYPO, \( 33.4 \pm 6.5; \) HYPER, \( 82.2 \pm 8.8; \ P<0.05, \) HYPER vs EUT, HYPO).
When release of cGMP from vascular smooth muscle was determined, cGMP concentration in the incubation medium was also elevated in HYPO (EUT, 0·057 ± 0·11 pmol/ml per mg wet weight, n = 7; HYPO, 0·110 ± 0·017, n = 9; HYPER, 0·072 ± 0·010, n = 8; P < 0·05, HYPO vs EUT).

Discussion

The key findings of this study are that capacities for both formation of and responding to NO in a rat arterial vessel are modulated by thyroid status. The hyperthyroid state was associated with increased capacity for NO formation, but reduced capacity for responding to NO, compared with the hypothyroid state. Capacity for NO formation, assessed by NOS activity, is primarily a property of the vascular endothelium. Capacity for responding to NO, estimated by NO donor-stimulated concentration of cGMP, resides in vascular smooth muscle. These data indicate that thyroid status affects more than the endothelial layer of the vascular wall, contrary to what a majority of previous studies had suggested.

Rat models of hypo- and hyperthyroidism

Treatment of rats with propylthiouracil was successful in inducing the hypothyroid state. Citrate synthase activity,
an index of oxidative capacity, was reduced in the soleus muscle of HYPO. This effect of hypothyroidism on mitochondrial protein content of skeletal muscle has been repeatedly reported for rodent muscle by us (Delp et al. 1995, McAllister et al. 1995b, 2000) and others (e.g. Ianuzzo et al. 1977). Conversely, treatment with triiodothyronine was associated with increased citrate synthase activity, as reported previously by us (McAllister et al. 1995c, 1998, 2000) and others (e.g. Ianuzzo et al. 1977). HYPO also exhibited blunted growth; in addition, HYPER demonstrated left ventricular hypertrophy. These findings, all hallmarks of hypo- and hyperthyroidism, indicate that our rat models of thyroid disease are valid.

Capacity for NO formation

Although neither hypo- nor hyperthyroid status significantly altered NOS activity relative to the euthyroid state, the capacity for NO formation was clearly greater in aortae from HYPER than in those from HYPO. Our findings for aortic NOS activity in different thyroid states resemble those reported by Quesada et al. (2002). Further, these findings are consistent with earlier findings concerning vascular function. We (Delp et al. 1995, McAllister et al. 2000) and others (Vargas et al. 1995) have found endothelium-dependent dilation of rat vasculature to be blunted in hypothyroidism; conversely, we (McAllister et al. 1998, 2000) and others (Scivoletto et al. 1986, Vargas et al. 1995, Honda et al. 2000) have observed augmented endothelium-dependent vasodilation in the hyperthyroid state. Since a primary mediator of endothelium-dependent dilation in vasculature of the rat is NO (Delp et al. 1993), our findings collectively suggest that alterations in endothelium-dependent vasodilation with changes in thyroid status are, in part, accounted for by an altered capacity for NO formation. It is clear, however, that changes in NO formation do not solely account for altered endothelium-dependent vasodilation. Vascular function

Figure 4 Immunohistochemical analysis of Euthyroid, Hypothyroid and Hyperthyroid aortae for eNOS. Vascular lumen located at the top of each panel; non-immune panel represents section not incubated with antibody to eNOS. Note positive staining for eNOS in endothelium of vascular wall.
studies have demonstrated differences in endothelium-dependent dilation among EUT, HYPO and HYPER, whereas NOS activity in the present study only differed significantly between HYPO and HYPER. Changes in formation of vasodilatory prostaglandins and/or endothelium-derived hyperpolarizing factors may also contribute to alterations in endothelium-dependent vasodilation with altered thyroid status.

Interestingly, both eNOS and nNOS protein expression were modulated in HYPO and HYPER in a manner consistent with NOS activity. Our data for NOS activity represent capacity for Ca\(^{2+}\)-dependent NO formation; eNOS and nNOS are Ca\(^{2+}\)-dependent isoforms of this enzyme (cf. Pollock et al. 1991). While the significance of modulation of eNOS expression for endothelium-dependent vasodilation is clear, that of alterations in nNOS expression with changes in thyroid status is less clear. It has been postulated that nNOS, which appears to be expressed only in vascular smooth muscle, may modulate contractile mechanisms (Brophy et al. 2000). Our immunohistochemical findings are in agreement with this earlier study; indeed, there was a marked increase in nNOS expression in vascular smooth muscle of HYPER aorta (Fig. 5). While the functional significance of this finding is uncertain, increased nNOS expression likely contributed to greater Ca\(^{2+}\)-dependent NOS activity in HYPER.

Modulation of eNOS and nNOS expression by thyroid status may involve several stimuli, two of which are thyroid hormone concentration and chronic level of blood flow/shear stress. Hypo- and hyperthyroidism have effects on protein expression in most tissues (Yen 2001); their effects on skeletal muscle metabolic and contractile protein expression are particularly well established (Ianuzzo et al. 1977, Caiozzo & Haddad 1996). It is unknown whether thyroid hormone affects protein expression in the vascular wall. Effects of chronically increased blood flow/shear stress on the vascular endothelium are better understood.

Figure 5 Immunohistochemical analysis of Euthyroid, Hypothyroid and Hyperthyroid aortae for nNOS. Vascular lumen located at top of each panel; non-immune panel represents a section not incubated with antibody to nNOS. Note positive staining for nNOS in smooth muscle of vascular wall, and greater staining for nNOS in the Hyperthyroid panel.
Studies using cultured endothelial cells exposed to increased shear stress (Nishida et al. 1992, Noris et al. 1995, Ranjan et al. 1995, Uematsu et al. 1995), and whole blood vessels studied in vitro after a period of chronically increased blood flow (Miller et al. 1986, Miller & Vanhoutte 1988, Miller & Burnett 1992, Nadaud et al. 1996), have reported increased endothelium-dependent vasodilation, increased NOS activity, and/or increased eNOS expression. It is therefore possible that increased cardiac output, a feature of human hyperthyroidism (Martin et al. 1991) and animal models of the disease (cf. Morkin et al. 1983), led to increased eNOS expression in HYPER via a chronic increase in shear stress on the aortic endothelium.

**Response to NO**

An unexpected finding in this study was that thyroid status also modulated the response of vascular smooth muscle to NO. While aortae from EUT, HYPO and HYPER all demonstrated large increases in cGMP concentration upon stimulation with an NO donor (i.e. stimulated vs basal cGMP concentrations), the increase in HYPO was markedly greater than that in HYPER (Fig. 6A). Normalizing cGMP concentration to tissue weight, rather than tissue protein concentration, did not change this finding. We were, however, unable to confirm depressed capacity for cGMP formation in HYPER when we determined cGMP release from vascular smooth muscle. Nonetheless, our data uniformly indicate that capacity for cGMP formation is increased in HYPO. This finding was unexpected, since we have previously found that aortae from hypothyroid rats (Delp et al. 1995, McAllister et al. 2000) exhibit normal relaxation responses to sodium nitroprusside at the same concentration used in the present study to stimulate GC. Further, we found that GC protein expression was similar among EUT, HYPO and HYPER, a finding inconsistent with alterations in the capacity for stimulated cGMP formation. Differences in breakdown of cGMP do not underlie our findings, since we included isobutyl-methylxanthine, a phosphodiesterase inhibitor, in our assay system to eliminate cGMP breakdown as a confounding variable. These findings emphasize the complexity of vascular cGMP formation and may indicate that acute regulation of GC (e.g. phosphorylation of GC, cytosolic Ca\(^{2+}\) concentration; cf. Friebe & Koessling 2003), rather than simple modulation of GC protein amount, is most important in determining cGMP formation in different thyroid states.

**Perspectives**

Exercise intolerance in hypothyroidism appears to be largely accounted for by cardiovascular dysfunction. Skeletal muscle blood flow during exercise is blunted (McAllister et al. 1995b), as is endothelium-dependent vasodilation (Delp et al. 1995, Vargas et al. 1995, McAllister et al. 2000). Conversely, hyperthyroidism is associated with augmented muscle blood flow during exercise (Frey 1967, McAllister et al. 1995c) and with enhanced endothelium-dependent vasodilation (Scivietto et al. 1986, Vargas et al. 1995, McAllister et al. 1998, 2000, Honda et al. 2000). Our findings for NOS activity, as well as for eNOS and nNOS protein expression, suggest that changes in capacity for NO formation contribute to alterations in endothelium-dependent vasodilation in hypo- and hyperthyroidism. They may, therefore, contribute to the mechanistic basis for altered skeletal muscle blood flow during exercise in thyroid disease states.

**Acknowledgements**

The technical assistance of Amy Barker, Emily Buhr, Stephanie Coover and Kasee Hildenbrand is gratefully acknowledged. Also acknowledged is provision of equipment essential to the conduct of this research by Drs Lisa Freeman and George Stewart.

**Funding**

This research was supported by NIH HL 57226 and AHA-KS-98-GB-25, as well as by a Research Career Enhancement Award from the American Physiological
Society. T K S was a Howard Hughes Medical Institute (HHMI) Research Scholar, supported by a HHMI Undergraduate Biology Education Program grant to Kansas State University. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References


Caiazzo VJ & Haddad F 1996 Thyroid hormone: modulation of muscle structure, function, and adaptive responses to mechanical loading. Exercise and Sport Sciences Reviews 24 321–361.


Morkin E, Flink IL & Goldman S 1983 Biochemical and physiologic effects of thyroid hormone on cardiac performance. Progress in Cardiovascular Disease 25 435–464.


Yen PM 2001 Physiological and molecular basis of thyroid hormone action. Physiological Reviews 81 1097–1142.

Received 9 December 2004
Accepted 6 January 2005